TMS Co

TMS Co Market Cap per Employee

The Market Cap per Employee of TMS Co (4891.T) as of Nov 4, 2026 is 454.86 M JPY. In the previous year, Market Cap per Employee was 454.86 M JPY — a change of 0.00% (lower).

Market Cap per Employee

454.86 MJPY

YoY

0.00%

Last updated:

Market Cap per Employee of TMS Co is 2026 454.86 M JPY. Market Cap per Employee of TMS Co was 2025 454.86 M JPY. It decreases by 0.00% lower compared to the previous year.

The TMS Co Market Cap per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Cap per Employee
Date
Market Cap per Employee
Jan 1, 2021
454.86 M JPY
Jan 1, 2022
454.86 M JPY
Jan 1, 2023
454.86 M JPY
Jan 1, 2024
454.86 M JPY
Jan 1, 2025
454.86 M JPY
Jan 1, 2026
454.86 M JPY
The TMS Co Market Cap per Employee history
YEARMarket Cap per EmployeeYoY
454.86 MJPY0.00%
454.86 MJPY0.00%
454.86 MJPY0.00%
454.86 MJPY0.00%
454.86 MJPY0.00%
454.86 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Market Cap per Employee of TMS Co is 454.86 M JPY in 2026.

Market Cap per Employee of TMS Co changed from 454.86 M JPY to 454.86 M JPY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Market Cap per Employee TMS Co since 2006 – with annual values, charts, and detailed analysis.

Market cap per employee shows the market value attributed to each employee. Technology companies typically have higher values due to intellectual capital.

Market Cap per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Market Cap per Employee's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — TMS Co

All Key Metrics — TMS Co